FIRSTCIN

Description

Cefozopran hydrochloride, a third-generation parenteral cephalosporin, was launched in Japan for the treatment of severe infections in immunocompromised patients caused by staphylococci and enterococci. Cefozopran displays a vety broad antibacterial spectrum against Gram-positive and Gram-negative organisms. It is potently active against Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa and Citrobacter freundii, some of which are resistant to most other cephalosporins. The superior wide spectrum antibacterial activity is attributed to its high affinities for penicillin-binding proteins in various organisms. Cefozopran is resistant to hydrolysis by most chromosomal and plasmidmediated β-lactamases. Cefozopran is reportedly effective in treating patients with respiratory tract, urinary tract, obstetrical, gynecological, soft tissue, and surgical infections.

Originator

Takeda (Japan)

brand name

Fristcin